DEA Stalls Marijuana Rescheduling Despite Trump's "Expeditious" Executive Order

The Drug Enforcement Administration is dragging its feet on marijuana rescheduling despite a direct order from President Donald Trump to move "in the most expeditious manner" -- a delay that underscores either bureaucratic resistance or the administration's lack of follow-through on its own directives.

According to a joint status report filed Monday by DEA and cannabis reform advocates, the agency's interlocutory appeal process "remains pending" with no briefing schedule established. This marks the fifth such report filed with largely identical language, nearly a year after a former administrative law judge accepted the appeal.

The appeal centers on serious allegations: that DEA exhibited bias and engaged in improper communications with anti-rescheduling parties during the review process. These are not minor procedural complaints -- they go to the heart of whether the agency conducted a fair evaluation of marijuana's medical potential and abuse liability.

Trump issued an executive order more than three months ago directing the attorney general to enact marijuana rescheduling reform as quickly as possible. The DEA, which falls under the Department of Justice, appears to have simply ignored that directive. The agency controls the briefing schedule, meaning the delay is entirely within its power to resolve.

This isn't just bureaucratic foot-dragging -- it's a pattern. The rescheduling process has been mired in delays and procedural roadblocks since the Biden administration first initiated a review of marijuana's Schedule I classification. Schedule I drugs are defined as having no accepted medical use and high potential for abuse, a categorization that puts cannabis alongside heroin and LSD despite widespread medical use in dozens of states.

The proposed rescheduling would move marijuana to Schedule III, acknowledging its medical applications while maintaining federal control. But even that modest reform -- supported by the Department of Health and Human Services based on scientific review -- has stalled in DEA's administrative machinery.

For cannabis reform advocates, the delay is particularly galling given Trump's campaign rhetoric about supporting state-level marijuana legalization and his executive order claiming to prioritize the issue. If the administration cannot compel its own agencies to follow presidential directives, it raises questions about who is actually running federal drug policy.

The joint status reports filed by DEA and reform proponents are required by the administrative court's order, but they reveal nothing beyond the fact that nothing is happening. No briefing schedule. No timeline. No progress. Just the same boilerplate language filed month after month.

Meanwhile, the federal-state conflict over marijuana policy continues to create legal chaos. Thirty-eight states have legalized medical marijuana, and 24 have legalized recreational use, yet the federal government maintains that cannabis has no accepted medical use. This disconnect affects everything from banking access for legal cannabis businesses to veterans' ability to use medical marijuana without losing federal benefits.

The DEA's inaction also leaves unresolved the allegations of bias and improper communications that prompted the appeal in the first place. If agency officials were coordinating with anti-rescheduling advocates while supposedly conducting an impartial scientific review, that would represent a fundamental breach of administrative procedure. But without a briefing schedule, those allegations cannot be properly examined.

Trump's executive order was supposed to cut through this kind of bureaucratic resistance. Instead, it appears to have been filed away and forgotten by the very agencies tasked with implementing it. Whether that reflects deliberate defiance, institutional inertia, or the administration's failure to enforce its own directives is unclear.

What is clear is that nearly a year after accepting the appeal, and three months after a presidential order demanding speed, the DEA has made no discernible progress. The agency has the authority to set the briefing schedule. It chooses not to. And the Trump administration, despite its executive order, appears unwilling or unable to make its own appointees comply.

For anyone tracking whether this administration follows through on its stated priorities, the marijuana rescheduling delay offers a telling case study. Executive orders are only as meaningful as the enforcement behind them. So far, on this issue, there is none.